Q&A: NYU Langone Medical Center's Harvey Pass on miR-29c* and Mesothelioma Prognosis

Researchers from Rosetta Genomics, in collaboration with investigators from NYU Langone Medical Center, this week published data in Cancer Research demonstrating that the microRNA could be used as a prognostic biomarker in patients with mesothelioma.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.